MGMT and cancer: Yogananda et al. employed brain MR imaging and corresponding genomic information from 247 subjects from The Cancer Imaging Archive and The Cancer Genome Atlas of which 163 had a methylated MGMT promoter and developed a T2WI-only network (MGMT-net) to determine MGMT promoter methylation status and simultaneous single-label tumor segmentation [77].